Zobrazeno 81 - 90
of 318
pro vyhledávání: ''
Publikováno v:
Cardiovascular Drugs and Therapy. 17:415-425
AMP579, an adenosine A(1)/A(2A) receptor agonist, protects against myocardial infarction when given at the onset of reperfusion. However, it is unclear which receptor subtype mediates its protective actions. Anaesthetised rabbits were subjected to 30
Publikováno v:
Cardiovascular Drugs and Therapy. 17:287-290
Reducing the effects of angiotensin II by blockade of AT1-receptors may be superior to inhibition of angiotensin II formation by angiotensin converting enzyme (ACE) inhibitors in chronic heart failure (CHF) patients. However, the results of several t
Autor:
Allan Gaw
Publikováno v:
Cardiovascular Drugs and Therapy. 17:53-62
The association between low-density lipoprotein cholesterol (LDL-C) levels and risk of coronary heart disease (CHD) is well established and LDL-C-lowering is currently the primary target for the treatment of dyslipidemia. However, low levels of high-
Autor:
Lexin Wang
Publikováno v:
Cardiovascular Drugs and Therapy. 17:367-370
Aims: The primary aim of the study was to investigate the effect of carbachol on ventricular repolarisation in an intact animal heart.
Publikováno v:
Cardiovascular Drugs and Therapy. 17:249-255
Monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF) stimulate angiogenesis in ischemic tissues, and both of their expression are stimulated by angiotensin II. We measured the serum concentrations of MCP-1 and VEGF
Publikováno v:
Cardiovascular Drugs and Therapy. 17:115-121
Levosimendan, a new type of inodilator drugs, is known to activate membrane adenosine 3′,5′-triphosphate-sensitive potassium (KATP) channels in some vascular smooth muscles and causes vasorelaxation. The involvement of potassium channels in the m
Autor:
Arnaldo Pinelli, Boris Bertolini, Edgardo Bonacina, Livio Tomasoni, Sergio Brenna, Silvio Trivulzio, Roberto Accinni
Publikováno v:
Cardiovascular Drugs and Therapy. 17:15-23
Various experiments have shown that decreased nitric oxide values alter plasma lipid levels or coagulation parameters or blood pressure values or cause myocardial necrosis phenomena, but it is not clear whether these alterations are reciprocally conn
Autor:
Eftihia Sbarouni, Christos Kroupis, Panagiota Flevari, K. Koniavitou, Zenon S. Kyriakides, Dimitrios Th. Kremastinos
Publikováno v:
Cardiovascular Drugs and Therapy. 17:319-323
Purpose: Raloxifene is a selective estrogen receptor modulator and an attractive alternative to estrogen replacement as it obviates the need for a progestin and does not increase C-reactive protein levels. We compared the effects of simvastatin and r
Publikováno v:
Cardiovascular Drugs and Therapy. 17:25-30
Previous studies have suggested that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors attenuate ischemia-reperfusion injury by increasing the activity of endothelial nitric oxide synthase (eNOS). We assessed whether short-term
Publikováno v:
Cardiovascular Drugs and Therapy. 17:123-128
Recent studies have shown that statins seem to upregulate the endothelial NO synthase pathway (eNOS) and may, therefore, enhance NO availability, a direct scavenger of O2 − and an inhibitor of oxidative enzymes. Methods. To assess whether the oxida